AI Article Synopsis

  • * Researchers analyzed a total of 2,182 NGS results from 1,484 patients, finding HPV B19 in 39 samples from 33 patients, predominantly in cerebrospinal fluid and blood.
  • * The majority of those infected had underlying conditions that lowered their immunity and presented with symptoms like fever, anemia, and severe nervous system issues, with a significant number improving after antiviral treatment.

Article Abstract

Background: Human parvovirus B19 (HPV B19) is a single-stranded DNA virus. The detection rate of HPV B19 in the blood of healthy blood donors using PCR technology was reported to be 6.323/100000. However, that among hospitalized patients suspected of being infected with a pathogenic microorganism is unknown.

Methods: A retrospective analysis was conducted on 2,182 high-throughput NGS results for 1,484 inpatients admitted to the First Affiliated Hospital of Zhengzhou University from January 2020 to October 2021 who were suspected of being infected with a pathogenic microorganism, as well as on clinical data of some HPV B19-positive patients.

Results: Human parvovirus B19 was detected in 39 samples from 33 patients. The positivity rate was 2.22% among patients and 1.78% among samples. HPV B19 was detected in 20 cerebrospinal fluid samples, 13 blood samples, 3 alveolar lavage fluid samples, 2 tissue samples, and 1 throat swab. Based on clinical symptoms and NGS results, 16 patients were diagnosed with HPV B19 infection. The number of HPV B19 sequences in these patients was greater than 6, and the patients showed common symptoms such as fever (14 cases), anemia (11 cases), and severe nervous system symptoms such as meningoencephalitis (9 cases) and Guillain-Barré syndrome with peripheral motor and sensory nerve axon damage (4 cases). All 16 patients had experienced events likely to lead to decreased immunity (11 had a history of trauma/surgery/major disease, 4 had a history of precursor infection, and 3 had used immunosuppressants) and 7 had a history of blood transfusion during hospitalization. After treatment with antiviral drugs (12 cases) and intravenous human immunoglobulin (3 cases), of the 16 patients, 14 patients improved.

Conclusion: The HPV B19 infection rate in hospitalized patients suspected of microbial infection was 2.22%. Most patients with HPV B19 infection had a history of low immunity and blood transfusion. HPV B19 could be detected in various bodily fluids and tissues (especially cerebrospinal fluid) using NGS. Patients with severe HPV B19 infection may have nervous system damage such as Guillain-Barré syndrome and meningoencephalitis. Early diagnosis using NGS and treatment with antiviral drugs and immunoglobulin can improve prognosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812433PMC
http://dx.doi.org/10.3389/fcimb.2022.1083839DOI Listing

Publication Analysis

Top Keywords

hpv b19
36
b19 infection
20
patients
13
human parvovirus
12
b19
12
parvovirus b19
12
hospitalized patients
12
patients suspected
12
pathogenic microorganism
12
b19 detected
12

Similar Publications

This is a case report of a 6-year-old girl with relapsed B cell acute lymphoblastic leukemia in which adoptive cell therapy was applied successfully to treat refractory human parvovirus (HPV) B19 infection. Allogenic chimeric antigen receptor (CAR) T-cell therapy (bispecific CD19/CD22) was bridged to hematopoietic stem cell transplantation (HSCT) using a haploidentical paternal donor. However, HPV B19 DNAemia progressed and transfusion-related graft versus host disease occurred.

View Article and Find Full Text PDF

Public healthcare demands effective and pragmatic diagnostic tools to address the escalating challenges in infection management in resource-limited areas. Recent advances in clustered regularly interspaced short palindromic repeat (CRISPR)-based biosensing promise the development of next-generation tools for disease diagnostics, including point-of-care (POC) testing for infectious diseases. The currently prevailing strategy of developing CRISPR/Cas-based diagnostics exploits only the target identification and -cleavage activity of a CRISPR-Cas12a/Cas13a system to provide diagnostic results, and they need to be combined with an additional preamplification reaction to enhance sensitivity.

View Article and Find Full Text PDF
Article Synopsis
  • - The study investigates the potential link between various viral infections and papillary thyroid carcinoma (PTC), focusing on viruses like parvovirus B19, CMV, HSV-1/HSV-2, and HPV types 16 and 18.
  • - Using paraffin-embedded tissue from 40 PTC patients, the presence of viral DNA was analyzed through real-time PCR methods.
  • - Results showed only one case of HPV (2.5%) and six cases of parvovirus B19, while no HSV or CMV was detected, suggesting complex associations between these viruses and PTC that require further investigation.
View Article and Find Full Text PDF

Human parvovirus B19 infection in malignant and benign tissue specimens of different head and neck anatomical subsites.

Infect Agent Cancer

September 2023

Division of Medical Biotechnology, Department of Medical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

Article Synopsis
  • A study investigated the presence of human parvovirus B19 (B19V) in head and neck squamous cell carcinomas (HNSCCs) among Iranian patients, finding B19V DNA in 36.1% of the examined tumors.
  • * The research involved analyzing HNSCC specimens using advanced techniques and also included control samples from healthy individuals, revealing a significant difference in B19V positivity between patients and controls.
  • * Results suggested a strong association between B19V presence in tumor tissues and high-risk human papillomavirus (HPV) infection, emphasizing the need for further research to understand B19V's role in HNSCC development.*
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!